MétaCan
Menu
Back to cohort

Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial

2009· article· en· W2001467013 on OpenAlexaff
J P Ortonne, Cecilia Ganslandt, Jin Tan, Peter Nordin, Knud Kragballe, Siegfried Segaert

Bibliographic record

VenueJournal of the European Academy of Dermatology and Venereology · 2009
Typearticle
Languageen
FieldImmunology and Microbiology
TopicPsoriasis: Treatment and Pathogenesis
Canadian institutionsWindsor Clinical ResearchWestern University
FundersUniversity of California, San FranciscoLEO PharmaUniversity of Sheffield
KeywordsCalcipotriolScalpMedicineBetamethasone dipropionateBetamethasonePsoriasisDermatologyQuality of life (healthcare)Randomized controlled trialSurgeryInternal medicine

Abstract

fetched live from OpenAlex

Abstract Background Psoriasis vulgaris of the scalp has a significant psychosocial impact on individuals affecting their quality of life (QoL). A combination of calcipotriol and betamethasone dipropionate in a formulation suitable for treatment of scalp psoriasis has been developed. Objective To assess the impact of treatment with either calcipotriol plus betamethasone dipropionate scalp formulation or calcipotriol scalp solution on QoL in patients with scalp psoriasis (both within and between treatment groups). Methods This 8‐week, randomized, investigator‐blind study, compared the once‐daily, two‐compound scalp formulation (calcipotriol 50 µg/g plus betamethasone 0.5 mg/g as dipropionate; Xamiol ® , LEO Pharma A/S, Ballerup, Denmark) with twice‐daily calcipotriol scalp solution (50 µg/mL; Daivonex ® , LEO Pharma A/S) in patients with scalp psoriasis of at least moderate severity covering ≥ 10% of the scalp. QoL was assessed (weeks 0, 2, 4, 8) using the 36‐item Short Form Health Survey (version 2; SF‐36v2) and Skindex‐16. Results Treatment with the two‐compound scalp formulation ( n = 207) resulted in significant improvements from baseline on the SF‐36v2 (Physical Component Summary, P = 0.005, week 8; Mental Component Summary, P < 0.05, weeks 2, 4, 8). A significant change from baseline in the calcipotriol scalp solution group ( n = 105) was seen only on the Mental Component Summary ( P = 0.04, week 8). Change from baseline in Skindex‐16 was significantly in favour of the two‐compound scalp formulation. Change was significant on both total score and individual scales. Conclusion The two‐compound scalp formulation was superior to calcipotriol scalp solution in improving QoL in patients with scalp psoriasis. Conflict of interest declaration J.P. Ortonne has served as a paid speaker and consultant for LEO Pharma. C. Ganslandt is a salaried employee of LEO Pharma. J. Tan served as a speaker, investigator and advisory board member for LEO Pharma and received honoraria from LEO Pharma for these activities. P. Nordin served as a paid investigator for LEO Pharma in the clinical trial. K. Kragballe has served as a paid speaker and consultant for LEO Pharma. S. Segaert has served as a paid speaker, clinical investigator and consultant for LEO Pharma.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.118
Threshold uncertainty score0.540

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0030.000
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.016
GPT teacher head0.253
Teacher spread0.237 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations35
Published2009
Admission routes1
Has abstractyes

Explore more

Same venueJournal of the European Academy of Dermatology and VenereologySame topicPsoriasis: Treatment and PathogenesisFrench-language works237,207